Darolutamide with androgen deprivation therapy and definitive or salvage locoregional radiation therapyfor localised, very high-risk prostate cancer: Interim analysis of an international, placebo-controlled, randomised phase 3 trial (DASL-HiCaP; ANZUP1801)